Mini MRI, Massive Impact: Chipiron Raises $17M to Democratize Diagnostics

France Medtech startup Chipiron moves closer to global deployment of compact magnetic resonance imaging systems with hospital-ready prototypes and clinical trials set for 2026.

• In June 2025, Chipiron, Paris based company, announced the successful closing of $17 million Series A funding to accelerate the development of its miniaturized MRI scanner, the first device designed to make easily accessible across the world. This milestone totals the funding to $22 million, including equity and public support from European innovation programs.

This device has low-Tc SQUID volume gradiometer, patented superconducting sensor that operates in open environments, offering 10X better signal-to-noise ratio as compared to traditional magnetic resonance imaging systems. Chipiron aims to develop diagnostic tool into inclusive, mobile, and hospital friendly solution.

Disrupting the $7B Global MRI Systems Market Through Deeptech Excellence

The global magnetic resonance imaging systems market is valued at approximately $7 billion in 2024. Despite this demand, the adoption remains limited, primarily due to high equipment costs, space constraints, and need of shielded environments.

Chipiron’s mission is to disrupt this market is gaining momentum:

• 2020: Company was founded with mission for miniaturize MRI system

• 2021: $1.1 million pre-seed round for establishment of foundational tech

• 2022-2023: Company secured $1.1 million in non-dilutive public funding, and $2.7 million seed round led by Exor Ventures and Unruly Capital 

• 2024: Prototype of investigational device

• 2025: Secured $17 million Series A funding by Blast and EIC Fund, iXcore and public programs

• Early 2026: Opening of office in U.S., and pre-submission FDA

• Late 2026: FDA submission

• 2027: U.S. FDA clearance for the device

Reimagining MRI: Mobile, Inclusive, and Clinically Ready

Unlike traditional magnetic resonance imaging systems, Chipiron’s compact system offers new possibilities for patient inclusion:

• Patients with pacemakers or metal implants who are usually excluded from MRI scans

• Obese, claustrophobic, paediatric and elderly patients who often struggle with MRI scans

• Healthcare centers with limited physical space or infrastructure can now access high-precision diagnostic imaging

“By 2026, our team will validate the clinical efficacy of our platform through real-world imaging. This data will shape the product that will redefine medical imaging on global level.”

- Dimitri Labat, CSO and Co-founder of Chipiron

A New Era for Global Imaging: Inclusive Diagnostics for All

Chipiron’s miniaturized MRI device has the capability to double the global magnetic resonance imaging systems segment, enabling early disease detection in remote, underserved or infrastructure-constrained environments. Further, with support from European bodies and leading venture investors, the company is developing an entirely new ecosystem – one where medical imaging is no longer limited to large hospitals but also reaches every corner of the world. 

“We have invested in Chipiron because of its solid scientific foundation, brilliant team, and the transformational potential of its MRI platform.”

-Hervé Arditty, President of iXcore

“This investment is in line with our mission to fund European deeptech breakthroughs in high-impact sectors like medical technology. The company is poised to become a global reference in the democratization of diagnostic imaging.”

-Representative of EIC Fund

Thus, as MRI continues to be underutilized globally, Chipiron is reengineering both the technology and the business model – ensuring that no patient, clinic, or country in world is left behind in accessing the diagnostic gold standard.